secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2023-12-27T23:59:59+00:00
Accession:  0001104659-23-129338
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus receives FDA approval for UDENYCA ONBODY on-body injector
-----------------------------------------------------------------

- FDA approved UDENYCA ONBODY on December 26, 2023, a pegfilgrastim biosimilar to reduce febrile neutropenia after chemotherapy.
- Product includes indicator light, auditive signal, and automatic needle retraction to confirm dose and reduce needlestick risk.
- Commercial launch planned for Q1 2024.
- Approval supported by pharmacokinetic/pharmacodynamic bioequivalence and adhesive performance data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000110465923129338/0001104659-23-129338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000110465923129338/tm2333730d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-129338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer